AAPS PharmSciTech

, Volume 14, Issue 1, pp 19–28 | Cite as

Investigating Gabapentin Polymorphism Using Solid-State NMR Spectroscopy

  • Kassibla E. Dempah
  • Dewey H. Barich
  • Aditya M. Kaushal
  • Zhixin Zong
  • Salil D. Desai
  • Raj Suryanarayanan
  • Lee Kirsch
  • Eric J. MunsonEmail author
Research Article Theme: Quality by Design: Case Studies and Scientific Foundations


Solid-state NMR spectroscopy (SSNMR), coupled with powder X-ray diffraction (PXRD), was used to identify the physical forms of gabapentin in samples prepared by recrystallization, spray drying, dehydration, and milling. Four different crystalline forms of gabapentin were observed: form I, a monohydrate, form II, the most stable at ambient conditions, form III, produced by either recrystallization or milling, and an isomorphous desolvate produced from desolvating the monohydrate. As-received gabapentin (form II) was ball-milled for 45 min in both the presence and absence of hydroxypropylcellulose (HPC). The samples were then stored for 2 days at 50°C under 0% relative humidity and analyzed by 13C SSNMR and PXRD. High-performance liquid chromatography was run on the samples to determine the amount of degradation product formed before and after storage. The 1H T 1 values measured for the sample varied from 130 s for the as-received unstressed material without HPC to 11 s for the material that had been ball-milled in the presence of HPC. Samples with longer 1H T 1 values were substantially more stable than samples that had shorter T 1 values. Samples milled with HPC had detectable form III crystals as well. These results suggest that SSNMR can be used to predict gabapentin stability in formulated products.


grinding polymorphism relaxation time solid-state NMR stability 



We are grateful to the National Institute for Pharmaceutical Technology and Education and the U.S. Food and Drug Administration (FDA) for providing funds for this research. This study was funded by the FDA-sponsored contract #HHSF223200819929C “Development of Quality by Design (QbD) Guidance Elements on Design Specifications Across Scales with Stability Considerations.”

EJM is a partial owner of Kansas Analytical Services, a company that provides solid-state NMR services to the pharmaceutical industry. The results presented here are from EJM's academic work at the University of Kansas and the University of Kentucky, and no data from Kansas Analytical Services is presented here.


  1. 1.
    Reece HA, Levendis DC. Polymorphs of gabapentin. Acta Crystallogr C. 2008;64(3):o105–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Hsu CH, Ke WT, Lin SY. Progressive steps of polymorphic transformation of gabapentin polymorphs studied by hot-stage FTIR microspectroscopy. J Pharm Pharm Sci. 2010;13(1).Google Scholar
  3. 3.
    Wenger M, Bernstein J. An alternate crystal form of gabapentin: a cocrystal with oxalic acid. Cryst Growth Des. 2008;8(5):1595–8.CrossRefGoogle Scholar
  4. 4.
    Reddy LS, Bethune SJ, Kampf JW, Rodriguez-Hornedo N. Cocrystals and salts of gabapentin: pH dependent cocrystal stability and solubility. Cryst Growth Des. 2008;9(1):378–85.CrossRefGoogle Scholar
  5. 5.
    Lin S-Y, Hsu C-H, Ke W-T. Solid-state transformation of different gabapentin polymorphs upon milling and co-milling. Int J Pharm. 2010;396(1–2):83–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Cutrignelli A, Denora N, Lopedota A, Trapani A, Laquintana V, Latrofa A, et al. Comparative effects of some hydrophilic excipients on the rate of gabapentin and baclofen lactamization in lyophilized formulations. Int J Pharm. 2007;332(1):98–106.PubMedCrossRefGoogle Scholar
  7. 7.
    Zong Z, Desai SD, Kaushal AM, Barich DH, Huang H-S, Munson EJ, et al. The stabilizing effect of moisture on the solid-state degradation of gabapentin. AAPS PharmSciTech. 2011;12:924–31. doi: 10.1208/s12249-011-9652-8.PubMedCrossRefGoogle Scholar
  8. 8.
    Braga D, Grepioni F, Maini L, Rubini K, Polito M, Brescello R, et al. Polymorphic gabapentin: thermal behaviour, reactivity and interconversion of forms in solution and solid-state. New J Chem. 2008;32(10):1788–95.CrossRefGoogle Scholar
  9. 9.
    Lubach JW, Xu D, Segmuller BE, Munson EJ. Investigation of the effects of pharmaceutical processing upon solid-state NMR relaxation times and implications to solid-state formulation stability. J Pharm Sci. 2007;96(4):777–87.PubMedCrossRefGoogle Scholar
  10. 10.
    Ibers JA. Gabapentin and gabapentin monohydrate. Acta Crystallogr C. 2001;57(5):641–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Barich DH, Gorman EM, Zell MT, Munson EJ. 3-Methylglutaric acid as a 13C solid-state NMR standard. Solid State Nucl Magn Reson. 2006;30(3–4):125–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Pines A, Gibby MG, Waugh JS. Proton-enhanced nuclear induction spectroscopy 13C chemical shielding anisotropy in some organic solids. Chem Phys Lett. 1972;15(3):373–6.CrossRefGoogle Scholar
  13. 13.
    Pines A. Proton-enhanced NMR of dilute spins in solids. J Chem Phys. 1973;59(2):569. doi: 10.1063/1.1680061.CrossRefGoogle Scholar
  14. 14.
    Andrew ER, Bradbury A, Eades RG. Removal of dipolar broadening of nuclear magnetic resonance spectra of solids by specimen rotation. Nature. 1959;183(4678):1802–3. doi: 10.1038/1831802a0.CrossRefGoogle Scholar
  15. 15.
    Dixon WT, Schaefer J, Sefcik MD, Stejskal EO, McKay RA. Total suppression of sidebands in CPMAS C-13 NMR. J Magn Reson. 1982;49(2):341–5. 1969.Google Scholar
  16. 16.
    Fung BM, Khitrin AK, Ermolaev K. An improved broadband decoupling sequence for liquid crystals and solids. J Magn Reson. 2000;142(1):97–101.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen Y-Y, Luo S-Y, Hung S-C, Chan SI, Tzou D-LM. 13C Solid-state NMR chemical shift anisotropy analysis of the anomeric carbon in carbohydrates. Carbohydr Res. 2005;340(4):723–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Barich DH, Davis JM, Schieber LJ, Zell MT, Munson EJ. Investigation of solid-state NMR line widths of ibuprofen in drug formulations. J Pharm Sci. 2006;95(7):1586–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Stephenson GA, Forbes RA, Reutzel-Edens SM. Characterization of the solid state: quantitative issues. Adv Drug Deliv Rev. 2001;48(1):67–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Hurst VJ, Schroeder PA, Styron RW. Accurate quantification of quartz and other phases by powder X-ray diffractometry. Anal Chim Acta. 1997;337(3):233–52.CrossRefGoogle Scholar
  21. 21.
    Campbell Roberts SN, Williams AC, Grimsey IM, Booth SW. Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry‚ exploring preferred orientation effects. J Pharm Biomed Anal. 2002;28(6):1149–59.PubMedCrossRefGoogle Scholar
  22. 22.
    Anwar J, Tarling SE, Barnes P. Polymorphism of sulfathiazole. J Pharm Sci. 1989;78(4):337–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Brunsteiner M, Jones AG, Pratola F, Price SL, Simons SJR. Toward a molecular understanding of crystal agglomeration. Cryst Growth Des. 2005;5(1):3–16. 2004.CrossRefGoogle Scholar
  24. 24.
    Gorman EM. Solid-state physical form detection and quantitation of pharmaceuticals in formulations [3449658]. PhD Dissertation Lawrence: University of Kansas; 2011.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2012

Authors and Affiliations

  • Kassibla E. Dempah
    • 1
    • 2
  • Dewey H. Barich
    • 2
  • Aditya M. Kaushal
    • 3
  • Zhixin Zong
    • 4
  • Salil D. Desai
    • 4
  • Raj Suryanarayanan
    • 3
  • Lee Kirsch
    • 4
  • Eric J. Munson
    • 1
    • 5
    Email author
  1. 1.Department of Pharmaceutical SciencesUniversity of KentuckyLexingtonUSA
  2. 2.Department of Pharmaceutical ChemistryUniversity of KansasLawrenceUSA
  3. 3.Department of PharmaceuticsUniversity of MinnesotaMinneapolisUSA
  4. 4.Division of PharmaceuticsUniversity of IowaIowa CityUSA
  5. 5.LexingtonUSA

Personalised recommendations